The current results indicated that NKp30 overexpression in the absence of IL-2 supplementation could improve NK cytotoxicity against THP-1 AML cells expressing moderate levels of the NKp30 ligand B7-H6. This evidence concerns the gene IL2 and acute myeloid leukemia.